Endo International (ENDP) Has Catalysts Despite NT Weakness - Guggenheim

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/15/2026

1. NVDA
2. SPY
3. CRWV
4. BAC
5. RKLB
6. BLK
7. RXRX
8. NOW
9. CAT
10. FMC

Go back to Endo International (ENDP) Has Catalysts Despite NT Weakness - Guggenheim

Oppenheimer Remains Sidelined as Endo Int'l (ENDP) Shares Trade Down

March 21, 2016 10:08 AM EDT

Oppenheimer reiterated a Perform rating on Endo International plc (NASDAQ: ENDP) as shares trade down following Valeant's announcement that it was reducing its guidance. Endo management also announced a 1Q16 guidance revision. Management slightly decreased 1Q revenue guidance to ~21-22% of FY16 total revenues, and outlined sales of ~$928-$972M (vs. prior ~22% of... More

Endo Int'l (ENDP), Horizon (HZNP), Mallinckrodt (MNK) on Watch with Valeant (VRX) Halted

March 21, 2016 8:30 AM EDT

Endo Int'l (NASDAQ: ENDP), Horizon Pharma (NASDAQ: HZNP) and Mallinckrodt (NYSE: MNK) are on watch with Valeant halted, news pending

... More

UPDATE: Endo (ENDP) Downgraded From Top Pick to Outperform at RBC Following Recent Update

March 18, 2016 6:38 AM EDT

(Updated - March 18, 2016 8:37 AM EDT)

RBC Capital downgraded Endo International plc (NASDAQ: ENDP) from Top Pick to Outperform with a price target of $47.00 (from $73.00). Analyst Randall Stanicky noted that shares are down 29% due to a sector pull-back tied to Valeant Pharma's sell-off. Endo also recently... More